As we conclude the first month of 2025, it is a great time to reflect on the transformative journey of 2024 and set our sights for the year ahead. The past year was marked by significant achievements in innovation, collaboration, and growth—each bringing us closer to our goal of fundamentally reshaping the pharmaceutical industry. Looking further into 2025, we are excited about the opportunities that await us and remain committed to driving groundbreaking innovation and delivering impactful solutions for the industry.

2024 brought significant advancements in both business and technology for ArgusEye. It was the year we successfully doubled our team, relocated to new facilities, and had our first product launch—a productive year to say the least!

Here is a closer look at some of the milestones that defined 2024:

At the start of the year, we took a monumental step forward by relocating from a shared laboratory at Linköping university to our own 700m² facility, housing laboratories, production facilities, and several office spaces. This move was more than just a change of address, it is a testament to the tangible growth and expansion the company is experiencing. Our new premises provide plenty of office and laboratory space for continued innovation and growth in the coming years.

In May, we closed an oversubscribed funding round of €2.8 million. The round was led by Voima Ventures, a Nordic early-stage investor specializing in science-driven innovation, and co-lead with Eir Ventures, a leading Scandinavian life science venture capital fund. This investment is crucial for scaling our operations and further developing the Auga™ platform, as we strive to deliver a comprehensive solution for the entire pharmaceutical process chain.

To meet the increasing demand for our solutions, we achieved significant growth in our workforce, more than doubling the size of our team in just one year. This expansion has brought a wealth of diverse talent and expertise into ArgusEye, further strengthening our ability to innovate, execute, and deliver exceptional results.

One of the year’s standout moments was the launch of the Auga™ platform and AugaOne™. Auga™ is a versatile sensor platform designed for real-time bioprocess monitoring, while AugaOne™ is the first product in the lineup—a standalone sensor system that seamlessly integrates with chromatography equipment, providing valuable in-line data in real-time during product purification. This launch represents a significant milestone in our objective to develop a versatile technology that can be seamlessly integrated throughout the bioprocess.

Explore the Auga™ platform
Explore AugaOne™

Throughout the year, we conducted several successful demonstrations for some of the world’s leading pharmaceutical companies. While we have continued our demonstrations in Europe, we also held our first demonstrations in the U.S., spanning from the East Coast to the West Coast. These demonstrations have further validated the potential of our technology and opened new opportunities for collaboration within the U.S. market.

For the third consecutive year ArgusEye secured a spot on Ny Teknik’s prestigious ‘33-Listan’ and by that earned the elusive status of a ‘gold company’. The list showcases Sweden’s most promising young tech companies, each eligible for up to three appearances, with progressively stricter criteria applied each time. Being recognized on the list for three consecutive years highlights the significant progress we have made and emphasizes the rapid pace at which we achieved this growth.

With a year of impressive achievements behind us, we are more inspired than ever to push boundaries in 2025. Our focus will remain on advancing our technologies, expanding our reach, and delivering solutions that empower the pharmaceutical industry to thrive. We are dedicated to continue this journey of innovation and collaboration, fueled by the belief that the best is yet to come.

While we can’t predict the future, we are committed to several key goals this year. One major focus is expanding our team and expertise to accelerate our progress even further and we plan to grow our sensor lineup. Additionally, an exciting milestone awaits—a highly anticipated product launch, marking the release of our second portfolio product.